• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
Classification Nameprosthesis, spinous process spacer/plate
Generic Nameprosthesis, spinous process spacer/plate
1351 calle avanzado suite 100
san clemente, CA 92673
PMA NumberP140004
Date Received03/31/2014
Decision Date05/20/2015
Product Code
NQO[ Registered Establishments with NQO ]
Docket Number 15M-1957
Notice Date 06/18/2015
Advisory Committee Orthopedic
Clinical Trials NCT00692276
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the superion interspinous spacer (iss). This device is indicated to treat skeletally mature patients suffering from pain, numbness, and/or cramping in the legs (neurogenic intermittent claudication) secondary to a diagnosis of moderate degenerative lumbar spinal stenosis, with or without grade 1 spondylolisthesis, confirmed by x-ray, mri and/or ct evidence of thickened ligamentum flavum, narrowed lateral recess, and/or central canal or foraminal narrowing. The superion® iss is indicated for those patients with impaired physical function who experience relief in flexion from symptoms of leg/buttock/groin pain, numbness, and/or cramping, with or without back pain, and who have undergone at least 6 months of non-operative treatment. The superion® iss may be implanted at one or two adjacent lumbar levels in patients in whom treatment is indicated at no more than two levels, from l1 to l5. For this intended use, moderate degenerative lumbar spinal stenosis was defined as follows:1) 25% to 50% reduction in the central canal and/or nerve root canal (subarticular, neuroforaminal) compared to the adjacent levels on radiographic studies, with radiographic confirmation of any one of the following:a) evidence of thecal sac and/or cauda equina compression;b) evidence of nerve root impingement (displacement or compression) by either osseous or non-osseous elements; andc) evidence of hypertrophic facets with canal encroachment. 2) and associated with the following clinical signs:a) presents with moderately impaired physical function (pf) defined as a score of >= 2. 0 of the zurich claudication questionnaire (zcq); andb) ability to sit for 50 minutes without pain and to walk 50 feet or more.
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
Labeling Part 2
Post-Approval StudyShow Report Schedule and Study Progress
Supplements: S001 S002 S003 S004